ReviewJournal of hepatocellular carcinoma2018
Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist.
Review in Journal of hepatocellular carcinoma, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Diagnostic Value of Circulating microRNAs for Hepatocellular Carcinoma: Results of a Meta-analysis and Validation.Biochemical genetics · 2026Pooled it
- Beta-adrenergic receptor blockers and hepatocellular carcinoma survival: a systemic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.The Cochrane database of systematic reviews · 2022Pooled it
- Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.The Cochrane database of systematic reviews · 2021Pooled it
- Explainable artificial intelligence and ensemble learning for hepatocellular carcinoma classification: State of the art, performance, and clinical implications.World journal of hepatology · 2025Review
- Targeting Glypican-3 for Liver Cancer Therapy: Clinical Applications and Detection Methods.Journal of clinical and translational hepatology · 2025Review
- Targeting Glypican-3 in Liver Cancer: Groundbreaking Preclinical and Clinical Insights.Biomedicines · 2025Review
- The Anticancer Journey of Liquiritin: Insights into Its Mechanisms and Therapeutic Prospects.Current medicinal chemistry · 2025Review
- Review
- Patterns and Clinicopathological Features of Histologically Proven Metastases in Hepatocellular Carcinoma.Cureus · 2024Article
- Feeding artery: a valuable feature for differentiation of regenerative nodule, dysplastic nodules and small hepatocellular carcinoma in CEUS LI-RADS.European radiology · 2024Article
- Primary liver cancer spectrum: current knowledge and the next steps.Hepatobiliary surgery and nutrition · 2024Article
- Feasibility of large language models for CEUS LI-RADS categorization of small liver nodules in patients at risk for hepatocellular carcinoma.Frontiers in oncology · 2024Article
- Diagnostic performance of AI-based models versus physicians among patients with hepatocellular carcinoma: a systematic review and meta-analysis.Frontiers in artificial intelligence · 2024Review
- Carcinoma of unknown primary (CUP): an update for histopathologists.Cancer metastasis reviews · 2023Review
- Article
- Article
- Artificial intelligence in the detection, characterisation and prediction of hepatocellular carcinoma: a narrative review.Translational gastroenterology and hepatology · 2022Review
- Article
- Arginase-1 and P-glycoprotein are downregulated in canine hepatocellular carcinoma.Journal of veterinary science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histopathologists retain a critical role in the diagnosis and management of hepatocellular carcinoma (HCC). HCC arises usually but not exclusively in a background of advanced-stage chronic liver disease. The histological diagnosis of HCC poses many challenges particularly when dealing with liver biopsy specimens due to the heterogeneity of HCC and the difficulty to confirm hepatocellular differentiation in some instances. Primary liver tumors should be considered as a continuum with typical hepatocellular and cholangiocarcinoma at the two ends and a whole range of tumors showing both hepatocellular and cholangiocellular differentiation with or without an associated progenitor/stem cell component in the middle. Characterization of combined (or mixed) hepatocellular-cholangiocarcinoma can be very challenging. In advanced-stage chronic liver disease, the main challenge for the histopathologist is still to differentiate between HCC and its precursors, although this is rarely critical in the clinical setting at present. HCC originating in non-cirrhotic livers needs to be differentiated from other primary and extrahepatic tumors and from hepatocellular adenoma, bearing in mind that progression to malignancy is more through a continuum that watertight histological categories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.